Cargando…

Spotlight on Pimavanserin Tartrate and Its Therapeutic Potential in the Treatment of Major Depressive Disorder: The Evidence to Date

Major depressive disorder (MDD) is widely prevalent and one of the leading causes of disability. Treatment outcomes remain suboptimal with 1 in 3 patients with MDD responding inadequately to commonly used antidepressants. Pimavanserin, an atypical antipsychotic that modulates serotonergic neurotrans...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soogrim, Vicki, Ruberto, Valerie L, Murrough, James, Jha, Manish Kumar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812044/ https://www.ncbi.nlm.nih.gov/pubmed/33469267 http://dx.doi.org/10.2147/DDDT.S240862

Ejemplares similares

Effect of pimavanserin on anxious depression in patients with major depression and an inadequate response to previous therapy: secondary analysis of the clarity study
por: Papakostas, George I., et al.
Publicado: (2020)

Development of a UPLC–MS/MS method for determination of pimavanserin tartrate in rat plasma: Application to a pharmacokinetic study
por: Wang, Shixiao, et al.
Publicado: (2017)

Pharmacological Treatments for Patients with Treatment-Resistant Depression
por: Ruberto, Valerie L., et al.
Publicado: (2020)

Spotlight on elotuzumab in the treatment of multiple myeloma: the evidence to date
por: Weisel, Katja
Publicado: (2016)

Spotlight on sirukumab for the treatment of rheumatoid arthritis: the evidence to date
por: Lazzerini, Pietro Enea, et al.
Publicado: (2016)

Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date
por: Crotti, Chiara, et al.
Publicado: (2017)

Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date
por: Galluzzo, M, et al.
Publicado: (2019)

Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis
por: Tampi, Rajesh R, et al.
Publicado: (2019)

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date
por: Akamine, Takaki, et al.
Publicado: (2018)

Spotlight on fevipiprant and its potential in the treatment of asthma: evidence to date
por: Kao, Christina C, et al.
Publicado: (2019)

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

Spotlight on pembrolizumab in non-small cell lung cancer: the evidence to date
por: Vachhani, Pankit, et al.
Publicado: (2016)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
por: Machado, Álvaro, et al.
Publicado: (2018)

Spotlight on valsartan–sacubitril fixed-dose combination for heart failure: the evidence to date
por: Vilela-Martin, José Fernando
Publicado: (2016)

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
por: Cinti, Francesca, et al.
Publicado: (2017)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
por: Lenert, Aleksander, et al.
Publicado: (2017)

Spotlight on bevacizumab and its potential in the treatment of malignant pleural mesothelioma: the evidence to date
por: Levin, Pavel A, et al.
Publicado: (2017)

Review Article “Spotlight on Ultrasonography in the Diagnosis of Peripheral Nerve Disease: The Evidence to Date”
por: Hannaford, Andrew, et al.
Publicado: (2021)

Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date
por: Gajofatto, Alberto
Publicado: (2017)

Spotlight on copanlisib and its potential in the treatment of relapsed/refractory follicular lymphoma: evidence to date
por: Mensah, Felix A, et al.
Publicado: (2018)

Pimavanserin: Potential Treatment For Dementia-Related Psychosis
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Dementia-related psychosis and the potential role for pimavanserin
por: Cummings, Jeffery L., et al.
Publicado: (2022)

Pimavanserin for Psychosis in Parkinson’s Disease-Related Disorders: A Retrospective Chart Review
por: Sellers, Jessie, et al.
Publicado: (2019)

Spotlight on aldoxorubicin (INNO-206) and its potential in the treatment of soft tissue sarcomas: evidence to date
por: Cranmer, Lee D
Publicado: (2019)

Spotlight on anifrolumab and its potential for the treatment of moderate-to-severe systemic lupus erythematosus: evidence to date
por: Felten, Renaud, et al.
Publicado: (2019)

Spotlight on Tocilizumab in the Treatment of CAR-T-Cell-Induced Cytokine Release Syndrome: Clinical Evidence to Date
por: Si, Stephanie, et al.
Publicado: (2020)

Update on the treatment of Parkinson’s disease psychosis: role of pimavanserin
por: Combs, Brianna L, et al.
Publicado: (2017)

Pimavanserin Treatment for Parkinson's Disease Psychosis in Clinical Practice
por: Dashtipour, Khashayar, et al.
Publicado: (2021)

Long-term outcomes with pimavanserin for psychosis in clinical practice
por: Akbar, Umer, et al.
Publicado: (2022)

Pimavanserin and Parkinson’s Disease Psychosis: A Narrative Review
por: Rissardo, Jamir Pitton, et al.
Publicado: (2022)

Flupentixol tartrate
por: Yamuna, Thammarse S., et al.
Publicado: (2014)

An Open-Label, 8-Week Study of Safety and Efficacy of Pimavanserin Treatment in Adults with Parkinson’s Disease and Depression
por: DeKarske, Daryl, et al.
Publicado: (2020)

Repurposing Pimavanserin, an Anti-Parkinson Drug for Pancreatic Cancer Therapy
por: Ramachandran, Sharavan, et al.
Publicado: (2020)

Pimavanserin for the treatment of psychosis in Alzheimer’s disease: A literature review
por: Srinivasan, Shilpa, et al.
Publicado: (2020)

Pimavanserin in Parkinson’s Disease-induced Psychosis: A Literature Review
por: Patel, Rikinkumar S, et al.
Publicado: (2019)

Impact of specialty pharmacist integration on time to medication access for pimavanserin
por: Livezey, Sabrina, et al.
Publicado: (2019)

Pimavanserin: A Novel Autophagy Modulator for Pancreatic Cancer Treatment
por: Ramachandran, Sharavan, et al.
Publicado: (2021)

Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant
por: Jha, Manish Kumar
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8maggcq52nes60f7s6q032ufcp